APN-959038

APN-959038 is a small molecule antagonist of the C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5), developed for the treatment of inflammatory and fibrotic diseases. By simultaneously blocking CCR2 and CCR5, the drug aims to inhibit the recruitment and activation of monocytes and macrophages, which are key drivers of chronic inflammation and tissue fibrosis. This dual antagonism is hypothesized to provide superior efficacy compared to targeting either receptor alone, particularly in conditions like non-alcoholic steatohepatitis (NASH) or diabetic nephropathy, where both pathways contribute to disease progression. The compound was originally part of the development pipeline at Alpinion (or related entities) and has been investigated in preclinical and early clinical settings to evaluate its safety, pharmacokinetics, and potential to reduce inflammatory biomarkers.